Clinical trials: Severe Pneumonia
Community-acquired Pneumonia, Covid19
Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia
Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation.
- Trial name
- LPSARS2 (NCT04505605)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients
This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp…
- Trial name
- NCT04336254
- Testing
- allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Renmin Hospital of Wuhan University
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.
- Trial name
- NCT05938075
- Testing
- VXCO-100, COVID-19 mRNA vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Covid19
The Impact of Vaccination on Severity of Illness in COVID-19
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus…
- Trial name
- NCT04912700
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 11,834 people
- Sponsor
- Corewell Health East
Sars-CoV2, Covid-19
Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients
The established Insight(TM) mHealth Platform, a component of the Stephenson Cancer Center (SCC) mHealth Shared Resource will be used to create the "Symptom Tracker" app.
- Trial name
- NCT04397614
- Testing
- mHealth Assessments
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Oklahoma
Ventilator-associated Pneumonia
Prevention Ventilator Associated Pneumonia
The objective of the investigators work was to evaluate the impact of 4 sequentially implemented measures for preventing VAP in a major heart surgery ICU.
- Trial name
- REINA (NCT02060045)
- Testing
- Bundle implementation
- Where
- Spain
- Volunteers
- 1,534 people
- Sponsor
- Maria Jesus Perez
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).
- Trial name
- NCT04366830
- Testing
- Remestemcel-L
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Severe Acute Respiratory Syndrome Coronavirus 2, Acute Respiratory Distress Syndrome
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), an emerging coronavirus, which has already infected 192 million people with a case fatality rate close to 2%.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
- Trial name
- FIBRO-COVID (NCT04987528)
- Testing
- Aminoterminal type III peptide of procollagen, Lung computed tomography
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hôpital Européen Marseille
Covid19, Severe Acute Respiratory Syndrome
Ivermectin in Adults With Severe COVID-19.
Since the onset of the disease, more than 40.5 million people have been diagnosed with COVID-19 and nearly 1.2 million people have died (October 21, 2020).
- Trial name
- NCT04602507
- Testing
- Ivermectin
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- CES University
Covid19, Cytokine Storm
Menstrual Blood Stem Cells in Severe Covid-19
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of menstrual blood stem cells.
- Trial name
- NCT05019287
- Testing
- Allogeneic human menstrual blood stem cells secretome, Intravenous saline injection
- Where
- Iran
- Volunteers
- 29 people
- Sponsor
- Avicenna Research Institute
SARS-CoV Infection, Acute Respiratory Distress Syndrome
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study to evaluate the efficacy and safety of glenzocimab in ARDS.
- Conditions
- SARS-CoV Infection, Acute Respiratory Distress Syndrome, COVID-19, ARDS
- Trial name
- GARDEN (NCT04659109)
- Testing
- glenzocimab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Acticor Biotech
COVID-19
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780463
- Testing
- MP0420, Remdesivir
- Where
- 105 sites in United States, Denmark and 8 more
- Volunteers
- 485 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Community-Acquired Pneumonia
Corticoids in Severe Community-Acquired Pneumonia (CAP)
The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V).
- Trial name
- NCT00908713
- Testing
- methylprednisolone
- Where
- 3 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Hospital Clinic of Barcelona
COVID-19
ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
Albertans with COVID-19 are at risk of deteriorating and developing severe illness. Those over age 40 or with co-morbid illness, and likely those who are immune suppressed, are at highest risk.
- Trial name
- NCT04329611
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Canada
- Volunteers
- 148 people
- Sponsor
- Dr. Michael Hill
COVID-19
Respiratory Physiotherapy in Severe COVID-19 Patients
COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS).
- Trial name
- FTR-COVID (NCT04459819)
- Testing
- Respiratory physiotherapy
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Influenza
Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults
Severe community-acquired pneumonia caused by influenza virus (hereafter referred to as severe influenza pneumonia) is a major etiology of community-acquired pneumonia leading to acute respiratory failure and ICU admission.
- Trial name
- CAPSTONE-IFV (NCT07351500)
- Testing
- Saline (0.9%, sterile, for infusion), low dose Methylprednisolone, Moderate dose Methylprednisolone
- Volunteers
- 496 people
- Sponsor
- Qingyuan Zhan
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
COVID-19 Pandemic
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.
- Trial name
- NCT05236309
- Testing
- Jing-Guan-Fang(JGF) : Chinese herbal decoction
- Where
- Taiwan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Taipei City Hospital
COVID-19 Severe Respiratory Failure
Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
In patients with COVID-19, severe hypoxemic respiratory failure (SRF) leading to invasive mechanical ventilation (IMV), raises the mortality rate substantially.
- Trial name
- NCT05279391
- Testing
- Dexamethasone, Low molecular weight heparin, Anakinra 100Mg/0.67Ml Inj Syringe
- Where
- Greece
- Volunteers
- 150 people
- Sponsor
- Democritus University of Thrace
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.